WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced eight presentations of clinical and pre-clinical data for tivantinib (ARQ 197) at the Annual Meeting of the American Association for Cancer Research (AACR), held from March 31 – April 4 in Chicago, Illinois. Tivantinib is an oral inhibitor of c-MET, a receptor tyrosine kinase, which is currently in Phase 3 clinical trials for non-squamous non-small cell lung cancer (NSCLC). Several other studies related to the Company’s earlier-stage product candidates and discovery platform will also be presented at AACR.
